PPARγ调节器预测器 (PGMP_v1):用于增强2型糖尿病管理的化学空间探索和计算见解
Sk Abdul Amin1, Lucia Sessa2, Shovanlal Gayen3
1Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 132, 84084, Fisciano, SA, Italy. pharmacist.amin@gmail.com.
Molecular diversity
|February 1, 2025
概括
这项研究引入了计算方法,以发现新的Peroxisome增殖器激活受体玛 (PPARγ) 调节器. 一个在线工具,PGMP_v1,帮助药物化学家设计更有效的药物治疗糖尿病等疾病.
科学领域:
- 计算化学是一种计算化学.
- 药品化学 药品化学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 氧酶增殖器激活受体玛 (PPARγ) 对于脂肪细胞的分化和胰岛素敏感性至关重要.
- 在形药物设计中,通过提供结构性见解,在优化方面提供优势.
研究的目的:
- 探索PPARγ调节器的化学空间,使用基于连接体的方法和分子对接组合 (MDEs).
- 开发一个监督机器学习 (ML) 模型来预测PPARγ调制器.
- 创建一个可访问的在线工具 (PGMP_v1),用于对PPARγ调节器的潜在选.
主要方法:
- 基于联结体的虚拟选.
- 分子对接组合 (MDEs) 用于相互作用分析.
- 监督机器学习模型开发.
- 化学空间网络分析.
- 在线PGMP_v1工具的开发.
主要成果:
- 确定PPARγ活动所必需的关键结构动机.
- 联合化学空间网络和ML模型的演示,用于快速选.
- 成功开发了用于预测PPARγ调节器的PGMP_v1工具.
结论:
- 计算方法,包括MDEs和ML,对于识别PPARγ调节器是有效的.
- 该PGMP_v1工具提高了科学界在药物发现中的可访问性.
- 这项工作推动了用于治疗应用的更强大的PPARγ调节器的设计.
相关概念视频
Glucagon-like Receptor Agonists
292
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
292
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Dipeptidyl Peptidase 4 Inhibitors
164
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
164
Oral Hypoglycemic Agents: Biguanides and Glitazones
162
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
162
Cell Specific Gene Expression
13.4K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.4K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K


